<?xml version="1.0" encoding="UTF-8"?>
<p>The age and gender distribution of the 761 followed-up household contacts are summarized in 
 <xref ref-type="table" rid="T2">Table 2</xref>. Information on AV prophylaxis was available for 587 contacts (
 <xref ref-type="table" rid="T2">Table 2</xref>, 
 <xref ref-type="table" rid="T3">Table 3</xref>); of the 444 contacts who named the AV they received, 435 received oseltamivir. Mean number of days from onset in the primary case-patient to starting prophylaxis in contacts was 4.4 days (SD 4.9, median 4 days, IQR 2–6 days) (
 <xref ref-type="fig" rid="F2">Figure 2</xref>). Compliance for use of AVs found 255 contacts with information on prophylaxis start and end dates, with a median time to receiving AV of 9 days (IQR 8–10). Only 8 contacts received treatment for &lt;5 days.
</p>
